Rossmore Private Capital’s Oramed Pharmaceuticals ORMP Stock Holding History

Rossmore Private Capital’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-40,661	Closed	-$186K	–	225
2022 Q2	$186K	Hold	40,661	–	–	0.03%	221
2022 Q1	$352K	Sell	40,661 -11,343	-22%	-$116K	0.05%	178
2021 Q4	$743K	Buy	52,004 +5,000	+11%	+$105K	0.12%	135
2021 Q3	$1.03M	Buy	47,004 +31,943	+212%	+$544K	0.18%	113
2021 Q2	$202K	Hold	15,061	–	–	0.03%	219
2021 Q1	$153K	Hold	15,061	–	–	0.03%	211
2020 Q4	$64K	Hold	15,061	–	–	0.01%	196
2020 Q3	$39K	Hold	15,061	–	–	0.01%	190
2020 Q2	$53K	Hold	15,061	–	–	0.01%	167
2020 Q1	$46K	Hold	15,061	–	–	0.02%	146
2019 Q4	$78K	Hold	15,061	–	–	0.02%	135
2019 Q3	$48K	Hold	15,061	–	–	0.02%	135
2019 Q2	$54K	Hold	15,061	–	–	0.02%	128
2019 Q1	$55K	Hold	15,061	–	–	0.02%	126
2018 Q4	$45K	Hold	15,061	–	–	0.02%	122
2018 Q3	$73K	Hold	15,061	–	–	0.03%	127
2018 Q2	$112K	Hold	15,061	–	–	0.07%	109
2018 Q1	$98K	Hold	15,061	–	–	0.1%	97
2017 Q4	$136K	Buy	+15,061	New	+$144K	0.14%	110

Other funds holding ORMP

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JSMC

Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Rossmore Private Capital's ORMP Position: Q3 2022 in Review

Rossmore Private Capital sold out of Oramed Pharmaceuticals (ORMP) in Q3 2022, closing a stake of 40,661 shares — an estimated $186K sold.

Rossmore Private Capital first reported a position in ORMP in Q4 2017 and held it in 19 quarters. The position peaked at $1.03M in Q3 2021. 71 funds tracked by Wall St. Rank hold ORMP as of Q3 2022.

Rossmore Private Capital reported no remaining Oramed Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Rossmore Private Capital sold 40,661 Oramed Pharmaceuticals shares in Q3 2022, an estimated $186K.
Rossmore Private Capital first reported a position in Oramed Pharmaceuticals in Q4 2017 and held it in 19 quarters.
Rossmore Private Capital's Oramed Pharmaceuticals position peaked at $1.03M in Q3 2021.
71 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2022.

Based on Rossmore Private Capital's 13F filing for Q3 2022, filed 8 Nov 2022.